We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Mulls Faster Pathway for Early-Stage Alzheimer’s Drugs
FDA Mulls Faster Pathway for Early-Stage Alzheimer’s Drugs
March 22, 2013
With Phase III flame-outs of Alzheimer’s treatments continuing to frustrate drugmakers, the FDA is considering applying a swifter, smoother approval process to such drugs.